Novartis AG was hobbled by a pair of phase III trial failures, as delpacibart etedesiran fell short in the Harbor trial testing the antibody oligonucleotide conjugate in myotonic dystrophy type 1 (DM1) and pelacarsen, partnered with Ionis Pharmaceuticals Inc., fizzled in the cardiovascular (CV) outcomes Horizon study trying the antisense oligonucleotide in patients with elevated lipoprotein (a).<\/p>\n
BioWorld<\/a> Clinical<\/a> Cardiovascular<\/a> Musculoskeletal<\/a> Europe<\/a> U.S.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Novartis AG was hobbled by a pair of phase III trial failures, as delpacibart etedesiran fell short in…\n","protected":false},"author":2,"featured_media":128252,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[16014,8086,3750,62564,8092,62199,62563,62566,197,62565,29200,62249,206,1078,57008,2278,62567],"class_list":["post-128251","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-antisense-oligonucleotides","tag-bioworld","tag-cardiovascular","tag-cardiovascular-outcomes-trial","tag-clinical","tag-del-desiran","tag-delpacibart-etedesiran","tag-dyne-therapeutics-inc","tag-europe","tag-lipoproteina","tag-musculoskeletal","tag-myotonic-dystrophy-type-1","tag-novartis","tag-novartis-ag","tag-pelacarsen","tag-u-s","tag-zeleciment-basivarsen"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117241341664563740","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/128251","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=128251"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/128251\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/128252"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=128251"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=128251"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=128251"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}